NICE Decision On Arthritis Opens Door For Biosimilars In England

UK Recommends Treating Moderate Rheumatoid Arthritis With Three Biologic Molecules

 
• By Dave Wallace

A decision by health technology assessment body NICE opens the door to broaden the use of adalimumab, etanercept and infliximab by using them to treat moderate as well as severe rheumatoid arthritis.

Pile of British money pounds sterling new one pound coins GBP in four piles close-up with NHS above. Rising cost of National Health Service concept UK
Certain biologics were found to be a cost-effective use of NHS resources for treating moderate rheumatoid arthritis

More from United Kingdom

More from Europe